Meg McKinley
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Meg McKinley has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Iona Cheng
Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, USA
12 shared publications - Scarlett Lin Gomez
Department of Epidemiology and Biostatistics University of California San Francisco San Francisco California USA
12 shared publications - Alison J. Canchola
Department of Epidemiology and Biostatistics, University of California, San Francisco (UCSF), San Francisco, California
11 shared publications - Erin Lynn Van Blarigan
Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California
11 shared publications - Katherine Lin
Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California
11 shared publications - Salma Shariff-Marco
Department of Epidemiology and Biostatistics, University of California , San Francisco, CA
11 shared publications
Latest Publications
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from Assessment of Rebound in Cancer Diagnoses in California in 2022, by Stage, Sociodemographic Factors, and Rurality
Characteristics of people diagnosed with invasive tumors in California in 2001 to 2019, 2020, 2021, and 2022.
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Assessment of Rebound in Cancer Diagnoses in California in 2022, by Stage, Sociodemographic Factors, and Rurality
Characteristics of people diagnosed with invasive tumors in California in 2001 to 2019, 2020, 2021, and 2022.
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Table S3 from Assessment of Rebound in Cancer Diagnoses in California in 2022, by Stage, Sociodemographic Factors, and Rurality
Ratio of observed / expected invasive tumors in the Greater Bay Area of California in 2022 overall and for 12 common cancers, by sociodemographic characteristics, stage at diagnosis, and rurality.
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Assessment of Rebound in Cancer Diagnoses in California in 2022, by Stage, Sociodemographic Factors, and Rurality
Ratio of observed / expected invasive tumors in the Greater Bay Area of California in 2022 overall and for 12 common cancers, by sociodemographic characteristics, stage at diagnosis, and rurality.
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Table S4 from Assessment of Rebound in Cancer Diagnoses in California in 2022, by Stage, Sociodemographic Factors, and Rurality
Ratio of observed / expected invasive tumors in the Los Angeles Cancer Surveillance Program in 2022, overall and for 12 common cancers, by sociodemographic characteristics and stage at diagnosis.
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Assessment of Rebound in Cancer Diagnoses in California in 2022, by Stage, Sociodemographic Factors, and Rurality
Ratio of observed / expected invasive tumors in the Los Angeles Cancer Surveillance Program in 2022, overall and for 12 common cancers, by sociodemographic characteristics and stage at diagnosis.
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Materials and Methods from Assessment of Rebound in Cancer Diagnoses in California in 2022, by Stage, Sociodemographic Factors, and Rurality
Details for the ICD-O-3 site and histology codes used to define the cancer types and the SEER*Stat variables used for analysis.
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Materials and Methods from Assessment of Rebound in Cancer Diagnoses in California in 2022, by Stage, Sociodemographic Factors, and Rurality
Details for the ICD-O-3 site and histology codes used to define the cancer types and the SEER*Stat variables used for analysis.
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Assessment of Rebound in Cancer Diagnoses in California in 2022, by Stage, Sociodemographic Factors, and Rurality
Background:The reduction in cancer cases in 2020 has been attributed to missed diagnoses during the pandemic, yet no rebound occurred in 2021. We examined whether cancer rebounded in California in 2022.Methods:Data on invasive tumors in California for 2001 to 2022 were obtained through the NCI Surveillance, Epidemiology, and End Results program. Expected cases for 2022 were calculated using joinpoint regression models based on trends from 2001 to 2021 (omitting 2020). We calculated the ratio of observed to expected (O/E) cases in 2022 and 95% confidence intervals (CI).Results:There was no overall difference in observed versus expected invasive tumors in California in 2022. However, lung cancer was 29% lower than expected in rural areas (O/E: 0.71; 95% CI, 0.39–0.95), uterine cancer was lower than expected in Los Angeles (O/E: 0.91; 95% CI, 0.86–0.96), and breast cancer was lower than expected in Greater California (O/E: 0.95; 95% CI, 0.90–0.98). Groups with more tumors observed than expected included unstaged colorectal cancer in Greater California (O/E: 1.54) and Los Angeles (O/E: 1.26), colorectal cancer among males (O/E: 1.12) and Asian Americans (O/E: 1.16) in the Greater Bay Area, localized melanoma in Greater California (O/E: 1.24), and prostate cancer among Hispanic males in Los Angeles (O/E: 1.24).Conclusions:Overall, observed invasive tumors did not differ from expected in California in 2022, but there was variation across demographic, regional, and clinical factors. The reduction in cancer cases in 2020 likely reflects multiple factors, including missed diagnoses and death due to competing causes.Impact:Continued close monitoring of cancer diagnoses is needed to inform cancer control strategies.
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Assessment of Rebound in Cancer Diagnoses in California in 2022, by Stage, Sociodemographic Factors, and Rurality
Background:The reduction in cancer cases in 2020 has been attributed to missed diagnoses during the pandemic, yet no rebound occurred in 2021. We examined whether cancer rebounded in California in 2022.Methods:Data on invasive tumors in California for 2001 to 2022 were obtained through the NCI Surveillance, Epidemiology, and End Results program. Expected cases for 2022 were calculated using joinpoint regression models based on trends from 2001 to 2021 (omitting 2020). We calculated the ratio of observed to expected (O/E) cases in 2022 and 95% confidence intervals (CI).Results:There was no overall difference in observed versus expected invasive tumors in California in 2022. However, lung cancer was 29% lower than expected in rural areas (O/E: 0.71; 95% CI, 0.39–0.95), uterine cancer was lower than expected in Los Angeles (O/E: 0.91; 95% CI, 0.86–0.96), and breast cancer was lower than expected in Greater California (O/E: 0.95; 95% CI, 0.90–0.98). Groups with more tumors observed than expected included unstaged colorectal cancer in Greater California (O/E: 1.54) and Los Angeles (O/E: 1.26), colorectal cancer among males (O/E: 1.12) and Asian Americans (O/E: 1.16) in the Greater Bay Area, localized melanoma in Greater California (O/E: 1.24), and prostate cancer among Hispanic males in Los Angeles (O/E: 1.24).Conclusions:Overall, observed invasive tumors did not differ from expected in California in 2022, but there was variation across demographic, regional, and clinical factors. The reduction in cancer cases in 2020 likely reflects multiple factors, including missed diagnoses and death due to competing causes.Impact:Continued close monitoring of cancer diagnoses is needed to inform cancer control strategies.
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from Assessment of Rebound in Cancer Diagnoses in California in 2022, by Stage, Sociodemographic Factors, and Rurality
Ratio of observed/expected invasive tumors in the Cancer Registry of Greater California in 2022, overall and for 12 common cancers, by sociodemographic characteristics, stage, and rurality.
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Assessment of Rebound in Cancer Diagnoses in California in 2022, by Stage, Sociodemographic Factors, and Rurality
Ratio of observed/expected invasive tumors in the Cancer Registry of Greater California in 2022, overall and for 12 common cancers, by sociodemographic characteristics, stage, and rurality.
- 17 December 2025
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 35 (3) , 415-419
Assessment of Rebound in Cancer Diagnoses in California in 2022, by Stage, Sociodemographic Factors, and Rurality
Background: The reduction in cancer cases in 2020 has been attributed to missed diagnoses during the pandemic, yet no rebound occurred in 2021. We examined whether cancer rebounded in California in 2022. Methods: Data on invasive tumors in California for 2001 to 2022 were obtained through the NCI Surveillance, Epidemiology, and End Results program. Expected cases for 2022 were calculated using joinpoint regression models based on trends from 2001 to 2021 (omitting 2020). We calculated the ratio of observed to expected (O/E) cases in 2022 and 95% confidence intervals (CI). Results: There was no overall difference in observed versus expected invasive tumors in California in 2022. However, lung cancer was 29% lower than expected in rural areas (O/E: 0.71; 95% CI, 0.39–0.95), uterine cancer was lower than expected in Los Angeles (O/E: 0.91; 95% CI, 0.86–0.96), and breast cancer was lower than expected in Greater California (O/E: 0.95; 95% CI, 0.90–0.98). Groups with more tumors observed than expected included unstaged colorectal cancer in Greater California (O/E: 1.54) and Los Angeles (O/E: 1.26), colorectal cancer among males (O/E: 1.12) and Asian Americans (O/E: 1.16) in the Greater Bay Area, localized melanoma in Greater California (O/E: 1.24), and prostate cancer among Hispanic males in Los Angeles (O/E: 1.24). Conclusions: Overall, observed invasive tumors did not differ from expected in California in 2022, but there was variation across demographic, regional, and clinical factors. The reduction in cancer cases in 2020 likely reflects multiple factors, including missed diagnoses and death due to competing causes. Impact: Continued close monitoring of cancer diagnoses is needed to inform cancer control strategies.
- 17 December 2025
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 35 (3) , 415-419
Assessment of Rebound in Cancer Diagnoses in California in 2022, by Stage, Sociodemographic Factors, and Rurality
Background: The reduction in cancer cases in 2020 has been attributed to missed diagnoses during the pandemic, yet no rebound occurred in 2021. We examined whether cancer rebounded in California in 2022. Methods: Data on invasive tumors in California for 2001 to 2022 were obtained through the NCI Surveillance, Epidemiology, and End Results program. Expected cases for 2022 were calculated using joinpoint regression models based on trends from 2001 to 2021 (omitting 2020). We calculated the ratio of observed to expected (O/E) cases in 2022 and 95% confidence intervals (CI). Results: There was no overall difference in observed versus expected invasive tumors in California in 2022. However, lung cancer was 29% lower than expected in rural areas (O/E: 0.71; 95% CI, 0.39–0.95), uterine cancer was lower than expected in Los Angeles (O/E: 0.91; 95% CI, 0.86–0.96), and breast cancer was lower than expected in Greater California (O/E: 0.95; 95% CI, 0.90–0.98). Groups with more tumors observed than expected included unstaged colorectal cancer in Greater California (O/E: 1.54) and Los Angeles (O/E: 1.26), colorectal cancer among males (O/E: 1.12) and Asian Americans (O/E: 1.16) in the Greater Bay Area, localized melanoma in Greater California (O/E: 1.24), and prostate cancer among Hispanic males in Los Angeles (O/E: 1.24). Conclusions: Overall, observed invasive tumors did not differ from expected in California in 2022, but there was variation across demographic, regional, and clinical factors. The reduction in cancer cases in 2020 likely reflects multiple factors, including missed diagnoses and death due to competing causes. Impact: Continued close monitoring of cancer diagnoses is needed to inform cancer control strategies.
- Open Access
- 9 January 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 1 from Disparities in Cancer Stage Shifts Associated with the COVID-19 Pandemic in California, 2020 to 2021
Supplemental Table 1. Population counts per pandemic time period and absolute change in percentage of late-stage cancer diagnoses for Post-Shutdown #2 and Post-Vaccine Rollout
- 9 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 1 from Disparities in Cancer Stage Shifts Associated with the COVID-19 Pandemic in California, 2020 to 2021
Supplemental Table 1. Population counts per pandemic time period and absolute change in percentage of late-stage cancer diagnoses for Post-Shutdown #2 and Post-Vaccine Rollout
- Open Access
- 9 January 2025
- Published by American Association for Cancer Research (AACR)
Data from Disparities in Cancer Stage Shifts Associated with the COVID-19 Pandemic in California, 2020 to 2021
Background:The COVID-19 pandemic and associated shutdowns disrupted healthcare access and resulted in decreased cancer screenings. Cancer diagnosis delays have concerning downstream effects on late-stage cancer, especially for marginalized populations.Methods:The study population included 349,458 adults in the California Cancer Registry diagnosed with cancer between January 2019 and December 2021, during which California experienced two stay-at-home orders. We examined the percentage of late-stage (III–IV) cancer diagnoses across five periods: Pre-pandemic (January 2019–February 2020), Shutdown #1 (March–June 2020), Post-shutdown #1 (July–November 2020), Post-shutdown #2 (December 2020–March 2021), and Post-vaccine rollout (April–December 2021). To examine the association between time period and late-stage diagnoses, we conducted a multivariable log-binomial regression model adjusted for sociodemographic and neighborhood factors.Results:The percentage of late-stage cancer diagnoses increased during Shutdown #1 (+5.2%) and returned to baseline Post-vaccine rollout. Groups with notably higher increases in the percentage of late-stage cancer (vs. overall population) during Shutdown #1 include Pacific Islander (+13.7%), Thai (+11.2%), Chinese (+8.1%), Native Hawaiian (+7.4%), Filipino (+6.6%), and uninsured (+7.4%). Uninsured [vs. private insurance; prevalence ratio (PR), 1.41], low neighborhood socioeconomic status (nSES; vs. high; PR, 1.19), and racial and ethnic minoritized groups (vs. non-Hispanic White; PR, 1.04–1.19) had higher likelihood for late-stage cancer diagnosis.Conclusions:The pandemic exacerbated late-stage cancer disparities for racial and ethnic minoritized groups, underinsured, and low nSES communities in California (2020–2021).Impact:Interventions to improve cancer screening must be focused on racial and ethnic minoritized, underinsured, and low nSES communities, as they are likely to be more vulnerable to healthcare disruptions like the pandemic.
- 9 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Disparities in Cancer Stage Shifts Associated with the COVID-19 Pandemic in California, 2020 to 2021
Background:The COVID-19 pandemic and associated shutdowns disrupted healthcare access and resulted in decreased cancer screenings. Cancer diagnosis delays have concerning downstream effects on late-stage cancer, especially for marginalized populations.Methods:The study population included 349,458 adults in the California Cancer Registry diagnosed with cancer between January 2019 and December 2021, during which California experienced two stay-at-home orders. We examined the percentage of late-stage (III–IV) cancer diagnoses across five periods: Pre-pandemic (January 2019–February 2020), Shutdown #1 (March–June 2020), Post-shutdown #1 (July–November 2020), Post-shutdown #2 (December 2020–March 2021), and Post-vaccine rollout (April–December 2021). To examine the association between time period and late-stage diagnoses, we conducted a multivariable log-binomial regression model adjusted for sociodemographic and neighborhood factors.Results:The percentage of late-stage cancer diagnoses increased during Shutdown #1 (+5.2%) and returned to baseline Post-vaccine rollout. Groups with notably higher increases in the percentage of late-stage cancer (vs. overall population) during Shutdown #1 include Pacific Islander (+13.7%), Thai (+11.2%), Chinese (+8.1%), Native Hawaiian (+7.4%), Filipino (+6.6%), and uninsured (+7.4%). Uninsured [vs. private insurance; prevalence ratio (PR), 1.41], low neighborhood socioeconomic status (nSES; vs. high; PR, 1.19), and racial and ethnic minoritized groups (vs. non-Hispanic White; PR, 1.04–1.19) had higher likelihood for late-stage cancer diagnosis.Conclusions:The pandemic exacerbated late-stage cancer disparities for racial and ethnic minoritized groups, underinsured, and low nSES communities in California (2020–2021).Impact:Interventions to improve cancer screening must be focused on racial and ethnic minoritized, underinsured, and low nSES communities, as they are likely to be more vulnerable to healthcare disruptions like the pandemic.
- Open Access
- 9 January 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 1 from Disparities in Cancer Stage Shifts Associated with the COVID-19 Pandemic in California, 2020 to 2021
Supplemental Figure 1. Age distributions from 2019 vs. 2021 from American Community Survey (ACS) 2019-2021
- 9 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 1 from Disparities in Cancer Stage Shifts Associated with the COVID-19 Pandemic in California, 2020 to 2021
Supplemental Figure 1. Age distributions from 2019 vs. 2021 from American Community Survey (ACS) 2019-2021